logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's VPRIV Shows Improvement In Gaucher-Related Bone Disease - Quick Facts

Shire plc (SHP.L,SHPGY: Quote) reported new data that demonstrate velaglucerase alfa for injection or VPRIV, the company's enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients. The data presented show that VPRIV improves Gaucher-related bone disease by a sustained increase in bone mineral density or BMD.

Results from a head-to-head Phase III study of VPRIV and Cerezyme, and follow-on extension trial of VPRIV, show a statistically significant improvement in lumbar spine BMD in Gaucher patients starting at nine months of treatment with VPRIV. Clinically and statistically significant improvement from baseline in mean LS Z-score was witnessed at 9 months of treatment with VPRIV, but not in the cohort of patients treated with Cerezyme.

In Gaucher disease patients, BMD is generally reduced compared to individuals without Gaucher disease, often resulting in lower Z-scores.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Internet video service Sling TV, on Wednesday said HBO would be available in time for the "Game of Thrones" and "Silicon Valley" season premieres on April 12, but did not specify a launch date. Memory chip maker Micron Technology, Inc. said Wednesday after the markets closed that its second quarter profit rose 28% from last year, helped by higher sales and lower income tax expenses. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales. Apple Watch is expected to post robust sales in the first weekend after its launch on April 24. A craze for Apple Watch may catapult the smartwatch industry into a lucrative market, while a not-so-impressive response for the Apple device may weigh on the industry.
comments powered by Disqus
Follow RTT